Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH CONEY

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1528007101
CMS profile
205024
Location
BEACHWOOD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$164,390.62

162 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Apellis Pharmaceuticals, Inc. $54,218.84 43
Regeneron Healthcare Solutions, Inc. $36,540.04 33
Genentech USA, Inc. $29,270.64 30
Genentech, Inc. $22,191.20 5
Astellas Pharma US Inc $9,531.21 9
Alimera Sciences, Inc. $8,731.25 18
ABBVIE INC. $2,804.84 9
F. Hoffmann-La Roche AG $549.21 8
ANI Pharmaceuticals, Inc. $188.67 1
Bausch & Lomb Americas Inc. $156.25 2
Dutch Ophthalmic, USA $132.88 1
Harrow Eye, LLC $27.87 1
Coherus Biosciences Inc. $25.80 1
Sandoz Inc. $21.92 1

Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH CONEY

NPI 1528007101 · CMS profile ID 205024

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

BEACHWOOD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1528007101?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH CONEY, NPI 1528007101, CMS profile ID 205024. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1528007101?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOSEPH CONEY, NPI 1528007101, CMS profile ID 205024. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1528007101?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOSEPH CONEY, NPI 1528007101, CMS profile ID 205024, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1528007101?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

162 matching records · $164,390.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 162 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 162.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $148.5106/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039670 CMS
Genentech USA, Inc. $6,720.0006/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039674 CMS
Genentech USA, Inc. $1,213.9706/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039678 CMS
Apellis Pharmaceuticals, Inc. $7,938.0006/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023825 CMS
Apellis Pharmaceuticals, Inc. $423.5806/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023829 CMS
Apellis Pharmaceuticals, Inc. $102.6006/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023817 CMS
Apellis Pharmaceuticals, Inc. $230.0006/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023837 CMS
Apellis Pharmaceuticals, Inc. $1,003.0006/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023843 CMS
ABBVIE INC. $102.4005/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103495684 CMS
Apellis Pharmaceuticals, Inc. $77.2805/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023793 CMS
Alimera Sciences, Inc. $20.3205/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092826067 CMS
Genentech USA, Inc. $18.7805/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039614 CMS
Genentech, Inc. $93.2405/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039702 CMS
ABBVIE INC. $30.1305/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103495682 CMS
Genentech USA, Inc. $28.7005/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039638 CMS
Regeneron Healthcare Solutions, Inc. $18.4105/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114028839 CMS
Alimera Sciences, Inc. $18.5005/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092831306 CMS
Genentech USA, Inc. $252.6805/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039642 CMS
Genentech USA, Inc. $129.6805/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039646 CMS
Genentech USA, Inc. $521.4105/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039650 CMS
Genentech USA, Inc. $26.2205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039654 CMS
Genentech USA, Inc. $6,720.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039658 CMS
Astellas Pharma US Inc $20.6804/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139335802 CMS
Alimera Sciences, Inc. $19.6204/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092834372 CMS
Alimera Sciences, Inc. $7.8004/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092835800 CMS
Apellis Pharmaceuticals, Inc. $5,670.0004/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023809 CMS
Apellis Pharmaceuticals, Inc. $0.8904/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023791 CMS
Apellis Pharmaceuticals, Inc. $17.1204/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023795 CMS
Astellas Pharma US Inc $61.4804/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139332704 CMS
Apellis Pharmaceuticals, Inc. $308.6804/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023827 CMS
Apellis Pharmaceuticals, Inc. $84.9404/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023831 CMS
Apellis Pharmaceuticals, Inc. $4,914.0004/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023841 CMS
Apellis Pharmaceuticals, Inc. $1,476.1704/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023845 CMS
Alimera Sciences, Inc. $17.7804/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092829502 CMS
Regeneron Healthcare Solutions, Inc. $17.6304/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114028837 CMS
Apellis Pharmaceuticals, Inc. $237.6503/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023807 CMS
Apellis Pharmaceuticals, Inc. $76.6203/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023833 CMS
Apellis Pharmaceuticals, Inc. $5,670.0003/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023815 CMS
Regeneron Healthcare Solutions, Inc. $30.4003/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114028835 CMS
Regeneron Healthcare Solutions, Inc. $122.6003/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114028833 CMS
Astellas Pharma US Inc $550.0003/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139454026 CMS
Genentech USA, Inc. $17.2603/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039634 CMS
ABBVIE INC. $27.5803/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103495680 CMS
Apellis Pharmaceuticals, Inc. $1,581.6203/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023805 CMS
Apellis Pharmaceuticals, Inc. $124.9903/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023819 CMS
Apellis Pharmaceuticals, Inc. $94.6703/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023821 CMS
Genentech USA, Inc. $42.0703/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133039682 CMS
Apellis Pharmaceuticals, Inc. $4,914.0002/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023823 CMS
Astellas Pharma US Inc $550.0002/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139454028 CMS
Apellis Pharmaceuticals, Inc. $124.4802/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154023811 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $132,316.74 164
PY2020 $47,615.73 59
PY2021 $115,542.78 112
PY2022 $188,086.01 145
PY2023 $147,517.26 158
PY2024 $164,390.62 162
PY2025 $184,698.46 172

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $28,683.39 10
PY2025 Principal investigator $203,638.53 33
PY2024 Recipient $22,159.72 14
PY2024 Principal investigator $95,752.56 21
PY2023 Recipient $2,205.25 2
PY2023 Principal investigator $241,148.98 19
PY2022 Principal investigator $188,009.80 17
PY2021 Principal investigator $221,237.92 4
PY2020 Principal investigator $170,491.88 3
PY2019 Principal investigator $8,448.74 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $6,077.16 12/15/2025 Non-covered Recipient Entity
Retina Associates of Cleveland
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236542
Principal investigator 1 Genentech, Inc. $3,781.53 11/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211643803
Principal investigator 1 Genentech, Inc. $228.80 11/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211643807
Principal investigator 1 Genentech, Inc. $3,927.02 11/20/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211643811
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363566
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363568
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363570
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 11/07/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363588
Principal investigator 1 Genentech, Inc. $5,921.00 10/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211643797
Principal investigator 1 Ocular Therapeutix, Inc. $85,361.78 10/15/2025 Non-covered Recipient Entity
Retina Associates of Cleveland
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236539
Principal investigator 1 ABBVIE INC. $13,035.73 10/10/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202516583
Principal investigator 1 ABBVIE INC. $3,913.51 10/01/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202512976
Recipient F. Hoffmann-La Roche AG $565.91 08/29/2025 Covered Recipient Physician Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US No dispute reported 06/30/2026 1211536904
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,000.00 08/01/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363564
Recipient F. Hoffmann-La Roche AG $561.67 08/01/2025 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211536915
Principal investigator 1 Genentech, Inc. $5,484.00 07/24/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211643790
Principal investigator 1 Apellis Pharmaceuticals, Inc. $577.00 07/23/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363430
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,976.00 07/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363456
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,430.00 07/16/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363458
Recipient Ocular Therapeutix, Inc. $18,105.18 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229304
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 06/20/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363534
Principal investigator 1 Ocular Therapeutix, Inc. $16,130.00 05/21/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236551
Principal investigator 1 ANI Pharmaceuticals, Inc. $12,227.90 05/15/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
New Day Study No dispute reported 06/30/2026 1248567411
Recipient F. Hoffmann-La Roche AG $266.56 05/05/2025 Covered Recipient Physician Faricimab DME Long Term Extension Rhone X No dispute reported 06/30/2026 1211536908
Recipient F. Hoffmann-La Roche AG $335.71 05/05/2025 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211536912
Principal investigator 1 Apellis Pharmaceuticals, Inc. $5,968.00 04/30/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363510
Principal investigator 1 Ocular Therapeutix, Inc. $7,861.95 04/02/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND INC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236547
Recipient F. Hoffmann-La Roche AG $6,502.00 03/31/2025 Covered Recipient Physician Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US No dispute reported 06/30/2026 1211536919
Recipient F. Hoffmann-La Roche AG $607.27 03/31/2025 Covered Recipient Physician Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US No dispute reported 06/30/2026 1211536922
Recipient F. Hoffmann-La Roche AG $565.91 03/31/2025 Covered Recipient Physician Clinical Features of Eyes that Participated in the RHONE-X Trial No dispute reported 06/30/2026 1211536927
Recipient F. Hoffmann-La Roche AG $565.91 03/31/2025 Covered Recipient Physician Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US No dispute reported 06/30/2026 1211536931
Recipient F. Hoffmann-La Roche AG $607.27 03/31/2025 Covered Recipient Physician Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US No dispute reported 06/30/2026 1211536935
Principal investigator 1 Genentech, Inc. $6,467.00 03/25/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211643786
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,462.00 03/14/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363486
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 03/14/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363488
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,276.00 02/19/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363472
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,926.00 02/19/2025 Non-covered Recipient Entity
Retina Associates of Cleveland, Inc
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363474
Principal investigator 1 ANI Pharmaceuticals, Inc. $1,495.37 01/30/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
New Day Study No dispute reported 06/30/2026 1248567467
Principal investigator 1 ANI Pharmaceuticals, Inc. $1,939.14 01/30/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
New Day Study No dispute reported 06/30/2026 1248567513
Principal investigator 1 Genentech, Inc. $223.08 01/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211643771
Principal investigator 1 Genentech, Inc. $2,725.54 01/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211643775
Principal investigator 1 Genentech, Inc. $1,324.02 01/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211643778
Principal investigator 1 Genentech, Inc. $384.00 01/28/2025 Non-covered Recipient Entity
RETINA ASSOCIATES OF CLEVELAND
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211643783

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2022 Amount invested $0.00 1
PY2022 Value of interest $50,000.00 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $50,000.00 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $50,000.00 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $50,000.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2019–2022

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2022 US Retina LLC $0.00 $50,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 951869143
PY2021 US Retina LLC $0.00 $50,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 856668671
PY2020 US Retina LLC $0.00 $50,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 714310971
PY2019 US Retina LLC $0.00 $50,000.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 655842133